AbbVie, Roche present positive Venclyxto results at ASCO

5th June 2019 Uncategorised 0

Venclyxto is a first-in-class targeted medicine designed to selectively bind and inhibit the B-cell lymphoma-2 protein.

More: AbbVie, Roche present positive Venclyxto results at ASCO
Source: News